Medpace Holdings (01P) Price & Analysis
01P Stock Chart & Stats
- Day’s Range
- EUR 586.80 - EUR 606.20
- 52-Week Range
- EUR 330.40 - EUR 623.40
- Previous Close
- EUR 614.00
- Volume
- 16
- Average Volume (3M)
- 9
- Market Cap
- EUR 16.28B
- Enterprise Value
- EUR 17.18B
- Total Cash (Recent Filing)
- EUR 705.32M
- Total Debt (Recent Filing)
- EUR 146.04M
- Price to Earnings (P/E)
- 35.5
- Beta
- 0.34
- Next Earnings
- Feb 15, 2027
- EPS Estimate
- 4.31
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Profitable Growth
MEDP has substantially expanded revenue while maintaining strong operating and net margins, indicating that scale is translating into durable earnings power. Continued profitability provides resources to support investment, absorb operating variability, and reinforce the company’s position in outsourced clinical development.
Backlog Supports Revenue Visibility
A large backlog and substantial near-term conversion provide meaningful visibility into future service revenue. Rising awards over the last twelve months also indicate ongoing demand, helping support workforce planning, capacity utilization, and continued growth across multi-year clinical programs.
Conservative Balance Sheet
Low leverage gives MEDP financial flexibility as it executes its growth strategy and manages normal fluctuations in clinical-program timing. Limited balance-sheet strain can reduce financing pressure, preserve capacity for investment, and improve resilience if client activity or project starts become less predictable.
Bears Say
Clinical-program Cancellations
Cancellations can reduce backlog and interrupt revenue conversion when client programs fail, encounter safety signals, or are reprioritized. Management identifies cancellations as a major factor behind the historical slowdown in growth, so persistent levels could pressure visibility and utilization over the next several quarters.
Customer Concentration
A meaningful share of revenue comes from a relatively small group of customers, increasing the effect that a major program change, cancellation, or reprioritization could have on results. Concentration can make backlog conversion, growth rates, and resource utilization more variable than the overall market opportunity suggests.
Expansion-related Cost Pressure
The Cincinnati expansion creates a known cost headwind before its benefits are fully reflected in operations. Approximately $20 million of additional 2027 expense could temper margin expansion and earnings growth, particularly if demand or project starts do not scale quickly enough to absorb the added capacity.
01P FAQ
What was Medpace Holdings’s price range in the past 12 months?
What is Medpace Holdings’s market cap?
When is Medpace Holdings’s upcoming earnings report date?
How were Medpace Holdings’s earnings last quarter?
Is Medpace Holdings overvalued?
Does Medpace Holdings pay dividends?
What is Medpace Holdings’s EPS estimate?
How many shares outstanding does Medpace Holdings have?
What happened to Medpace Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medpace Holdings?
What is the TipRanks Smart Score and how is it calculated?
Medpace Holdings Stock Smart Score
Company Description
Medpace Holdings
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle
- Employees
- 6,600
- Website
- www.medpace.com
- Address
- 5375 Medpace Way, Cincinnati, OH, 45227, US
Medpace Holdings (01P) Earnings & Revenues
01P Company Deck
01P Earnings Call
Earnings Call SentimentPositive
The call was broadly positive. Medpace reported strong revenue, EBITDA, net income, EPS, bookings, backlog, cash flow, pipeline activity, win rates, utilization, and employee retention, and raised its 2026 outlook. The main challenges were elevated-but-manageable cancellations, uncertainty that delayed 2027 guidance, quarter-to-quarter margin volatility, lower current metabolic awards, and approximately $20 million of operating costs from the Cincinnati expansion in 2027.
View all DE:01P earnings summaries01P Net sales Breakdown
- 98.00% U.S.
- 2.00% Other
01P Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 5 | 6 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 8 | 0 | 4 |